The Stomach Bug Infecting Half the World Is Quietly Damaging Your Liver

A bacterium that colonizes the stomachs of roughly half the global population is now linked to a substantially higher risk of developing fatty liver disease, according to a prospective study and meta-analysis published in Cancer Epidemiology, Biomarkers & Prevention. Led by Zhao L and colleagues at Weifang Medical University in China, the research followed more than 31,000 people over time and synthesized data from 43 independent studies, making it one of the most comprehensive investigations yet into the relationship between Helicobacter pylori and metabolic dysfunction-associated steatotic liver disease, or MASLD.

H. pylori Infection Linked to 63% Higher Odds of Fatty Liver Disease

The headline number from the meta-analysis is striking: pooling data across 43 studies, the researchers found a pooled odds ratio of 1.63 for MASLD in people infected with H. pylori compared to uninfected individuals. Among those with confirmed active infection, the odds climbed higher still, to a pooled OR of 1.70. The prospective cohort component, which tracked 31,048 participants in China using the 13C-urea breath test to diagnose infection and ultrasound to identify liver fat accumulation, found an adjusted hazard ratio of 1.15, meaning infected individuals were 15% more likely to develop MASLD over the follow-up period even after accounting for other risk factors.

H. pylori-positive individuals also showed consistently elevated blood glucose, low-density lipoprotein cholesterol, and blood pressure compared to uninfected participants, all established contributors to liver fat accumulation. One particularly notable mediator identified was the neutrophil-albumin ratio, or NAR, a marker of systemic inflammation that the study found partially explains the statistical pathway from H. pylori infection to MASLD development. Research into how H. pylori exacerbates MASLD via lipid metabolic pathways points specifically to the CagA virulence factor, a bacterial protein that appears to dysregulate hepatic lipid handling and worsen hepatic steatosis in infected individuals.

Why This Matters for 1.3 Billion People Already Living with MASLD

MASDL is not a niche condition. Estimates from The Lancet Gastroenterology put the global burden at approximately 1.3 billion people in 2023, with projections suggesting that figure could reach 1.8 billion by 2050 as obesity and type 2 diabetes rates continue rising. MASLD describes fat buildup in liver cells not caused by heavy alcohol use; left unchecked, it can progress to steatohepatitis, cirrhosis, and liver cancer. The condition is already the leading cause of chronic liver disease globally, imposing a substantial health and economic burden with an estimated overall prevalence of approximately 30%.

If H. pylori infection genuinely contributes to MASLD development, and this study argues it does, then treating or preventing the infection represents a potentially modifiable lever in a disease where therapeutic options remain limited. H. pylori is curable with a standard course of antibiotics and a proton pump inhibitor, a combination that eradicates the bacterium in most cases. The authors note that H. pylori eradication has been suggested in prior research to reduce MASLD risk, though large randomized trials confirming that endpoint have not yet been completed. Separate work examining persistent H. pylori infection and MASLD risk has similarly found that ongoing active infection, rather than past exposure, drives the association.

How a 31,048-Person Cohort Strengthened the Causal Case

The study's methodological strength lies in its prospective design. Unlike cross-sectional studies, which capture a single snapshot in time and cannot establish which condition came first, a prospective cohort measures exposures before outcomes occur, dramatically reducing the risk of reverse causation. Zhao and colleagues enrolled participants, confirmed their H. pylori status using the 13C-urea breath test, and then monitored them for MASLD diagnosis based on both ultrasound findings and metabolic criteria. Cox regression was used to estimate hazard ratios while adjusting for confounders. The systematic review layer, which pulled 43 existing studies into a meta-analysis, then tested whether the cohort finding held across diverse populations, study designs, and diagnostic methods.

The biological rationale also holds together across several pathways. H. pylori infection promotes chronic low-grade inflammation, disrupts the gut microbiome, increases intestinal permeability, and drives insulin resistance, each of which independently promotes fat accumulation in the liver. The CagA-positive strain of H. pylori appears particularly relevant: research on H. pylori and inflammatory pathways linked to metabolic steatohepatitis suggests the bacterium intensifies liver inflammation through inflammatory cytokine cascades, compounding the metabolic damage.

Limitations: Heterogeneity and Unanswered Mechanistic Questions

The study's authors are candid about its constraints. The meta-analysis pooled studies that varied considerably in sample size, diagnostic criteria for both H. pylori and MASLD, and participant demographics, producing meaningful heterogeneity across included studies. Some of the contributing studies were cross-sectional, which limits their individual contribution to causal inference even if the overall analysis benefits from the prospective cohort design. The precise mechanisms linking infection to liver fat accumulation also remain incompletely mapped. Prior reviews examining the mechanisms by which H. pylori aggravates fatty liver disease have flagged the roles of inflammatory cytokines and adipocytokines as areas needing more targeted study.

Genetic variation may also modulate how strongly H. pylori infection affects MASLD severity. The study notes that individuals carrying the G-allele of the PNPLA3 gene, a variant already associated with higher baseline MASLD risk, may experience a stronger interaction with H. pylori infection than those without it. Disentangling genetic susceptibility from infection-driven risk will require stratified analyses in future cohorts.

What Comes Next for H. pylori Eradication as a Prevention Strategy

The most clinically actionable implication is straightforward: clinicians managing patients at high MASLD risk should consider screening for H. pylori and treating active infection. The 15% increase in hazard and the 63% elevation in odds ratios are large enough to be clinically meaningful, especially in populations already burdened by obesity, hypertension, or type 2 diabetes. Whether routine eradication in otherwise asymptomatic carriers would reduce MASLD incidence at a population level is the next question the field needs to answer, and the authors call for randomized controlled trials designed specifically around that endpoint. Given that H. pylori treatment is low-cost, widely available, and already recommended for peptic ulcer disease and gastric cancer prevention, the barrier to testing this hypothesis is lower than for most pharmaceutical interventions.